SONROTOCLAX
| Brand name | BEQALZI |
|---|---|
| Active ingredient | SONROTOCLAX |
| Strength | 5MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | May 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11420968 | April 2039 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.